Stemtech Corporation Reports Q3 2025 Financial Results with Reduced Net Loss and Declining Sales

Stemtech Corporation reported its financial results for the third quarter of 2025, revealing a net loss of $812,541, a decrease from the $1,171,405 loss recorded in the same period of 2024. The company's net sales for the quarter were $852,300, down from $1,031,630 year-over-year. For the nine months ending September 30, 2025, Stemtech's net sales totaled $2,418,271, a significant decline from $3,740,000 in the prior year. The decrease in revenue is attributed to a strategic shift towards prioritizing long-term distributor quality and operational efficiency over short-term volume growth, which has led to a more selective market approach.

The company's cost of goods sold (COGS) for the third quarter was $169,817, a notable reduction from $380,205 in the previous year, reflecting a positive variance of $171,398. This improvement is attributed to enhanced efficiency and cost management strategies. Total operating expenses also decreased to $1,021,700 from $1,367,895, marking a reduction of $346,195, primarily due to strategic cuts in commissions and marketing expenses. Despite the decline in sales, the company has managed to improve its gross profit margin, which stood at $682,483 for the quarter.

In terms of operational metrics, Stemtech's current assets increased to $1,021,384 as of September 30, 2025, compared to $921,746 at the end of 2024. However, current liabilities rose to $10,301,779 from $9,009,049, leading to a working capital deficiency of approximately $9.2 million. The company has been actively engaged in discussions for a private placement of common stock, aiming to raise between $5 million and $7 million by the fourth quarter of 2025 to support working capital and inventory procurement.

Strategically, Stemtech has made significant moves to expand its market presence, including a joint venture in India and a licensing agreement in Taiwan. These initiatives are expected to enhance brand visibility and open new distribution channels while minimizing upfront cash investments. The company is also developing a Direct-to-Consumer marketing strategy to facilitate global distribution without the need for upfront inventory purchases. Looking ahead, management remains optimistic about the long-term benefits of its recalibration efforts, which are anticipated to strengthen customer engagement and retention, ultimately contributing to sustainable growth.